NovoCure Limited - Ordinary Shares (NVCR)

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

H.C. Wainwright raised the firm's price target on Novocure to $47 from $39 and kept a ‘Buy’ rating on the shares after the company announced FDA approval of Optune Pax.

The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of February 12, 2026. Introduction NovoCure Limited (NASDAQ: NVCR) stands as a unique outlier in the oncology landscape. Unlike the traditional pharmaceutical giants that dominate the space with [...]

The stock is on track to record its best day since December 2024 if the overnight gains hold.

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NovoCure (NVCR) Q3 2024 Earnings Call Transcript

Novocure (NVCR) Q2 2025 Earnings Call Transcript

NovoCure (NVCR) Q3 2025 Earnings Call Transcript

If you have decades of investing runway left, consider these two top healthcare stocks.

Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers.

Investment bank analysts up and down Wall Street are pounding the table on these stocks.